Powerful evidence supports the longterm prescription of angiotensinconverting enzyme (ACE) inhibitors in patients surviving an acute myocardial infarction (AMI) to enhance morbidity and survival outcomes. Nevertheless, while physicians are prescribing ACE-inhibitor therapy to many patients at high-risk of death, there continues to be a failure to prescribe appropriate ACE-inhibition regimens, resulting in an increase in subsequent patient death. Alternate use of an angiotensin receptor blocker (ARB) may be considered—though members of this class are also not readily interchangeable with each other or with the ACE inhibitors. The selective aldosterone antagonist eplerenone may represent a better alternative than do the ARBs for ACE-intolerant patients, though whatever the strategy, there is still the need to ensure that appropriate treatment dose and frequency are used...